560.    Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, Graham P, Thompson JF, Reisfeld RA, Kearsley J: Intralesional Targeted Alpha Therapy for Metastatic Melanoma. Cancer Biol Ther 2005;4.

561.    Allen JD, Zhang XD, Scott CL, Boyle GM, Hersey P, Strasser A: Is Apaf-1 expression frequently abrogated in melanoma? Cell Death Differ 2005;12:680-681.

562.    Becker TM, Ayub AL, Kefford RF, Mann GJ, Rizos H: The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired. Int J Cancer 2005;117:569-573.

563.    Becker TM, Rizos H, de la Pena A, Leclercq IA, Woodruff S, Kefford RF, Mann GJ: Impaired inhibition of NF-kappaB activity by melanoma-associated p16INK4a mutations. Biochem Biophys Res Commun 2005;332:873-879.

564.    Bourne RM, Stanwell P, Stretch JR, Scolyer RA, Thompson JF, Mountford CE, Lean CL: In vivo and ex vivo proton MR spectroscopy of primary and secondary melanoma. Eur J Radiol 2005;53:506-513.

565.    Byrne CM, Thompson JF, Johnston H, Hersey P, Quinn MJ, Michael Hughes T, McCarthy WH: Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research 2005;15:45-51.

566.    Chan ATC, Hsu M-M, Goh BC, Hui EP, Liu T-W, Millward MJ, Hong R-L, Whang-Peng J, Ma BBY, To KF, Mueser M, Amellal N, Lin X, Chang AY: Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.[see comment]. Journal of Clinical Oncology 2005;23:3568-3576.

567.    Clark J, Li W, Smith G, Shannon K, Clifford A, McNeil E, Gao K, Jackson M, Mo Tin M, O'Brien C: Outcome of treatment for advanced cervical metastatic squamous cell carcinoma. Head Neck 2005;27:87-94.

568.    de Wilt JH, Farmer SE, Scolyer RA, McCaughan BC, Thompson JF: Isolated melanoma in the lung where there is no known primary site: metastatic disease or primary lung tumour? Melanoma Res 2005;15:531-537.

569.    de Wilt JH, Farmer SJ, Scolyer RA, McCaughan BC, Thompson JF: Isolated melanoma in the lung where there is no known primary site; metastatic disease or primary lung tumour? Melanoma Res 2005;15:531-538.

570.    Francken AB, Hong AM, Fulham MJ, Millward MJ, McCarthy WH, Thompson JF: Detection of unsuspected spinal cord compression in melanoma patients by 18F-fluorodeoxyglucose-positron emission tomography. Eur J Surg Oncol 2005;31:197-204.

571.    Gillespie S, Zhang XD, Hersey P: Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Mol Cancer Ther 2005;4:668-676.

572.    Gillespie SK, Zhang XD, Hersey P: Ingenol 3-angelate induces dual modes of cell death and differentially regulates TRIAL-induced apoptosis in melanoma cells. Mol Cancer Ther 2005;3:668-676.

573.    Hersey P: Immunotherapy of melanoma - past, present and future. Cancer Forum 2005;29:90-93.

574.    Hersey P, Menzies SW, Coventry B, Nguyen T, Farrelly M, Collins S, Hirst D, Johnson H: Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunology, Immunotherapy 2005;54:208-218.

575.    Kefford R: Medical management of advanced melanoma. Cancer Forum 2005;29:86-89.

576.    Mann GJ: Genetic risk and melanoma. Cancer Forum 2005;29:68-70.

577.    Mansberg R, Crawford B, Uren RF, Thompson JF: Minimally Invasive Radio-Guided Surgery for Recurrent Thyroid Cancer Using Iodine-123. Clin Nucl Med 2005;30:43-44.

578.    McCarthy W: Developments in melanoma management - success and failure. Cancer Forum 2005;29:96-101.

579.    McKinnon JG, Starritt EC, Scolyer RA, McCarthy WH, Thompson JF: Histopathologic excision margin affects local recurrence rate: analysis of 2681 patients with melanomas < or =2 mm thick. Ann Surg 2005;241:326-333.

580.    Menzie SJ: Melanoma is not what it used to look like. Cancer Forum 2005;29:71-72.

581.    Menzies SW, Bischof L, Talbot H, Gutenev A, Avramidis M, Wong L, Lo SK, Mackellar G, Skladnev V, McCarthy W, Kelly J, Cranney B, Lye P, Rabinovitz H, Oliviero M, Blum A, Virol A, De'Ambrosis B, McCleod R, Koga H, Grin C, Braun R, Johr R: The performance of SolarScan: an automated dermoscopy image analysis instrument for the diagnosis of primary melanoma. Arch Dermatol 2005;141:1388-1396.

582.    Millward MJ, Joshua A, Kefford R, Aamdal S, Thomson D, Hersey P, Toner G, Lynch K: Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Invest New Drugs 2005;23:253-256.

583.    Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen D, Coventry BJ, Wang HJ: Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Annals of Surgery 2005;242:302-311; discussion 311-303.

584.    Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ: Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302-311; discussion 311-303.

585.    Morton DL, Cochran AJ, Thompson JF, Elashoff R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen D, Coventry BJ, Wang HJ: Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Annals of Surgery 2005;242:302-311; discussion 311-303.

586.    Morton DL, Thompson JF, Stretch J, McCarthy S: Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients. Cancer Forum 2005;29:76-81.

587.    Orange S, Rasko JE, Thompson JF, Vaughan J, Olive E, Pedler M, Horvath JS, Hennessy A: Interleukin-10 regulates arterial pressure in early primate pregnancy. Cytokine 2005;29:176-185.

588.    Pawlik TM, Ross MI, Shaw HM, Thompson JF, Gershenwald JE: Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol 2005;31:323-324.

589.    Pawlik TM, Ross MI, Thompson JF, Eggermont AM, Gershenwald JE: The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005;23:4588-4590.

590.    Scolyer R, Thompson J, Stretch JR, McCarthy SW: Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients. Cancer Forum 2005;29:76-81.

591.    Scolyer RA, Thompson JF: Desmoplastic melanoma: a heterogeneous entity in which subclassification as "pure" or "mixed" may have important prognostic significance. Ann Surg Oncol 2005;12:197-199.

592.    Scolyer RA, Thompson JF, McCarthy SW, Gershenwald JE, Ross MI, Cochran AJ: Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg 2005;201:821-823.

593.    Scolyer RA, Thompson JF, McCarthy SW, Gershenwald JE, Ross MI, Cochran AJ: Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients.[comment]. Journal of the American College of Surgeons 2005;201:821-823; author reply 823-824.

594.    Scolyer RA, Thompson JF, Stretch J: Collaboration between clinicians and pathologists: a necessity for the optimal management of melanoma patients. Cancer Forum 2005;29:76-81.

595.    Starritt EC, Uren RF, Scolyer RA, Quinn MJ, Thompson JF: Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:18-23.

596.    Stretch J, Thompson JF, Scolyer RA, Mountford C, Lean CL: Magnetic resonance spectroscopy in the management of melanoma. Cancer Forum 2005;29:73-76.

597.    Stretch JR, Somorjai R, Bourne R, Hsiao E, Scolyer RA, Dolenko B, Thompson JF, Mountford CE, Lean CL: Melanoma metastases in regional lymph nodes are accurately detected by proton magnetic resonance spectroscopy of fine-needle aspirate biopsy samples. Ann Surg Oncol 2005;12:943-949.

598.    Thompson JF, Menzies SW, Shaw HM, Scolyer RA, Kefford RF: Cutaneous melanoma; Authors' reply. The Lancet 2005;365:2004-2005.

599.    Thompson JF, Saw R, Stretch J: Current strategies for the surgical management of melanoma. Cancer Forum 2005;29:81-86.

600.    Thompson JF, Scolyer RA, Kefford RF: Cutaneous melanoma. Lancet 2005;365:687-701.

601.    Thompson JF, Shaw HM: Who should treat patients with primary melanoma? Br J Dermatol 2005;153:459-460; author reply 458-459.

602.    Thompson JF, Shaw HM: Who should treat patients with primary melanoma?[comment]. British Journal of Dermatology 2005;153:459-460; author reply 458-459.

603.    Thompson JF, Uren RF: Lymphatic mapping in management of patients with primary cutaneous melanoma. Lancet Oncol 2005;6:877-885.

604.    Thompson JF, Uren RF, Saw RP, Stevens GN: Internal mammary node metastasis from primary cutaneous melanoma on the anterior chest. ANZ J Surg 2005;75:723-725.

605.    Thompson JF, Uren RF, Scolyer RA, Stretch JR: Selective sentinel lymphadenectomy: progress to date and prospects for the future. Cancer Treatment & Research 2005;127:269-287.

606.    Thompson JF, Uren RF, Scolyer RA, Stretch JR: Selective sentinel lymphadenectomy: Progress to date and prospects for the future. in Leong SPL, Kitagawa Y, Kitajima M (eds): Selective Sentinel Lymphadenectomy for Human Solid Cancer.  New York: Springer, 2005.

607.    Uren RF, Howman-Giles RB, Chung D, Thompson JF: Role of lymphoscintigraphy for selective sentinel lymphadenectomy. Cancer Treatment & Research 2005;127:15-38.

608.    Uren RF, Howman-Giles RB, Chung D, Thompson JF: Role of lymphoscintigraphy for selective sentienl lymphadenectomy. in Leong SPL, Kitagawa Y, Kitajima M (eds): Selective Sentinel Lympadenectomy for Human Solid Cancer.  New York: Springer, 2005, 15-38.

609.    Van Poll D, Thompson JF, Colman M, McKinnon JG, Saw R, Stretch J, Scolyer RA, Uren R: A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:597-608.

610.    van Poll D, Thompson JF, Colman MH, McKinnon JG, Saw RP, Stretch JR, Scolyer RA, Uren RF: A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005;12:597-608.

611.    Weber F, Byrne SN, Le S, Brown DA, Breit SN, Scolyer RA, Halliday GM: Transforming growth factor-beta1 immobilises dendritic cells within skin tumours and facilitates tumour escape from the immune system. Cancer Immunology, Immunotherapy 2005;54:898-906.

612.    Wu JJ, Zhang XD, Gillespie S, Hersey P: Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Letters 2005;579:1940-1944.

613.    Yee VS, Thompson JF, McKinnon JG, Scolyer RA, Li LX, McCarthy WH, O'Brien CJ, Quinn MJ, Saw RP, Shannon KF, Stretch JR, Uren RF: Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 2005;12:429-439.

614.    Yee VSK, Thompson JF, McKinnon JG, Scolyer RA, Li L-XL, McCarthy WH, O'Brien CJ, Quinn MJ, Saw RPM, Shannon KF, Stretch JR, Uren RF: Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy.[erratum appears in Ann Surg Oncol. 2005 Oct;12(10):843]. Annals of Surgical Oncology 2005;12:429-439.

615.    Zhang XD, Wu JJ, Gillespie S, Borrow JM, Hersey P: Cross resistance of melanoma to TRIAL induced apoptosis and chemotherapy. in Giaccone G, Schilsky R, Sondel P (eds): Cancer Chemotherapy and Biological Response Modifiers.  New York: Elsevier, 2005, vol Annual 22.

616.    Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Palmer AA, Zhang XD, Thompson JF, Bron LP, Hersey P: Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005;58:1163-1169.